Anne Nunes - 11 Mar 2025 Form 4 Insider Report for Anika Therapeutics, Inc. (ANIK)

Role
SVP, Chief Operations Officer
Signature
/s/ Anne Nunes
Issuer symbol
ANIK
Transactions as of
11 Mar 2025
Net transactions value
-$12,626
Form type
4
Filing time
13 Mar 2025, 17:19:35 UTC
Previous filing
11 Mar 2025
Next filing
18 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANIK Common Stock Options Exercise $0 +2,561 +16% $0.000000 18,837 11 Mar 2025 Direct F1
transaction ANIK Common Stock Tax liability $12,626 -752 -4% $16.79 18,085 11 Mar 2025 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANIK Restricted Stock Unit Options Exercise $0 -2,561 -100% $0.000000 0 11 Mar 2025 Common Stock 2,561 $0.000000 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the third and final vesting installment of RSUs granted on March 11, 2022.
F2 Reflects an aggregate of 752 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 11, 2025.
F3 Reflects the closing price of ANIK common stock on March 11, 2025, the trading day to which the vesting of RSUs gave rise to tax withholding obligations.
F4 Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023.